drugset

drugset / Trial / NCT05725902

Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease

NCT05725902 ↗

Phase 2 Completed 12 enrolled Novo Nordisk A/S

NaSingle-groupOpen-labelTreatment

Summary

An open-label, single arm study in patients 12 to 21 years of age with SCD to evaluate the effects of etavopivat on cerebral and muscle hemodynamics.

Timeline

Start: 2024-03-09
Primary completion: 2026-03-09
Completion: 2026-03-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Etavopivat	Small molecule	400 mg	Oral

Indications